Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
The clinical study in France evaluated the safety and feasibility of Robocath’s robotic-assisted coronary intervention platform across complex cardiac cases.
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Subscribe To Our Newsletter & Stay Updated
